Intraperitoneal chemotherapy and immunotherapy.
1. The predictive model is validated empirically; a kinetic advantage for i.p. administration of certain antineoplastic drugs exist. 2. The concentrations achieved in the peritoneum are orders of magnitude greater than those found in the plasma, so rate-limiting systemic toxicities may be avoided. 3. The aspirin principle--if one is good, two are better--may not be applicable unless we can utilize this advantage to improve survival.